Finally, we enrolled an ESCC patient cohort 3 (n = 100, Table S4) to conduct an IHC staining assay study of FBL, and results confirmed its upregulated expression in ESCC tumors relative to NATs, as well as its usefulness as a prognostic biomarker (Figure 8E). Here, FBL is linked to esophageal squamous cell carcinoma.